OncoMatch/Clinical Trials/NCT05974774
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Is NCT05974774 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including iMAB and cMAB for prostate cancer.
Treatment: iMAB · cMAB — This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization. The primary goal of de-escalation is to investigate whether using an intermittent regime results in a similar OS to continuous treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage MHNPC
Metastatic disease required
Patient treated with ADT and an ARPI for mHNPC for 6-12 months... Patients with synchronous or metachronous metastases, high volume/risk or low volume/risk who fulfil the criteria can be included.
Prior therapy
Must have received: androgen deprivation therapy — mHNPC
Patient treated with ADT and an ARPI for mHNPC for 6-12 months
Must have received: androgen receptor pathway inhibitor — mHNPC
Patient treated with ADT and an ARPI for mHNPC for 6-12 months
Cannot have received: systemic anti-prostate cancer treatment not approved by EMA together with MAB
Patients who have received a systemic anti-prostate cancer treatment not approved by EMA together with MAB
Cannot have received: radical prostatectomy for M1 disease
Patients who have received...a radical prostatectomy for M1 disease
Cannot have received: bilateral orchiectomy
Patients who underwent or will undergo a bilateral orchiectomy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify